

# Fuzeon (enfuvirtide)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year
Medication	Quantity Limit
Fuzeon (enfuvirtide)	May be subject to quantity limit

## **APPROVAL CRITERIA**

Requests for Fuzeon (enfuvirtide) may be approved if the following criteria are met:

- I. Individual is using to treat human immunodeficiency virus (HIV) infection; **AND**
- II. Individual is using in combination with other antiretroviral agents; **AND**
- III. Individual has tried and failed at least three months of therapy with a regimen consisting of three or more antiretroviral agents;  
**OR**
- IV. Individual has viremia and confirmed resistance or intolerance to at least one antiretroviral agent from three different classes;  
  
**OR**
- V. Individual is using for postexposure prophylaxis of HIV infection following exposure to blood, tissues, or other body fluids associated with a risk for transmission of the HIV virus (AHFS, CDC, USPHS).

Fuzeon (enfuvirtide) may not be approved when the above criteria are not met and for all other indications.

State Specific Mandates		
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A

## **Key References:**

1. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. Available at: <https://stacks.cdc.gov/view/cdc/38856>. Accessed: October 19, 2018.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 18, 2018.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

5. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. *Infect Control Hosp Epidemiol.* 2013; 34:875-92.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.